EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone

Sanghoon Bae, Van-Hieu Mai, Seyoung Mun, Dalong Dong, Kyudong Han, Sunghyouk Park, Jung Keun Hyun iD

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.13665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Sanghoon Bae und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nanobiomedical Science & BK21 NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, Korea. Hauptthemen laut MEDLINE: Muscular Atrophy, Dexamethasone, Piperidines, Pyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation (NRF), Ministry of Science and ICT (MSIT), Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Muscle atrophy, including glucocorticoid‐induced muscle wasting from treatments such as dexamethasone (DEX), results in significant reductions in muscle mass, strength and function. This study investigates the potential of lonafarnib, a farnesyltransferase inhibitor, to counteract DEX‐induced muscle atrophy by targeting key signalling pathways.

Methods

We utilized in vitro models with C2C12 myotubes treated with DEX and in vivo models with Caenorhabditis elegans and DEX‐treated Sprague–Dawley rats. Myotube morphology was assessed by measuring area, fusion index and diameter. Muscle function was evaluated by grip strength and compound muscle action potential (CMAP) in the gastrocnemius (GC) and tibialis anterior (TA) muscles. Molecular mechanisms were explored through RNA sequencing and Western blotting to assess changes in mitochondrial function and muscle signalling pathways.

Results

Lonafarnib (2 μM) significantly improved myotube area (1.49 ± 0.14 × 10 5 μm 2 vs. 1.03 ± 0.49 × 10 5 μm 2 in DEX, p < 0.05), fusion index (18.73 ± 1.23% vs. 13.3 ± 1.56% in DEX, p < 0.05) and myotube diameter (31.89 ± 0.89 μm vs. 21.56 ± 1.01 μm in DEX, p < 0.05) in C2C12 myotubes. In C. elegans , lonafarnib (100 μM) increased the pharyngeal pumping rate from 212 ± 7.21 contractions/min in controls to 308 ± 17.09 contractions/min at day 4 ( p < 0.05), indicating enhanced neuromuscular function. In DEX‐induced atrophic rats, lonafarnib improved maximal grip strength (DEX: 13.91 ± 0.78 N vs. 1 μM lonafarnib: 16.18 ± 0.84 N and 5 μM lonafarnib: 16.71 ± 0.83 N, p < 0.05), increased muscle weight in GC, and enhanced CMAP amplitudes in both GC and TA muscles. Western blot analysis showed that lonafarnib treatment upregulated UCP3 and ANGPTL4 and increased phosphorylation of mTOR and S6 ribosomal protein ( p < 0.05), indicating enhanced mitochondrial function and protein synthesis. Knockdown models further demonstrated that lonafarnib could partially rescue muscle atrophy phenotypes, indicating its action through multiple molecular pathways.

Conclusions

Lonafarnib mitigates dexamethasone‐induced muscle atrophy by enhancing mitochondrial function and activating anabolic pathways. These findings support further investigation of lonafarnib as a therapeutic agent for muscle atrophy in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular AtrophyDexamethasonePiperidinesPyridinesAnimalsRatsDisease Models, AnimalMuscle Fibers, SkeletalCaenorhabditis elegansSignal TransductionCell LineMaleMiceDibenzocycloheptenes

Stichwörter der Autor:innen

ANGPLT4UCP3dexamethasonedrug repositioninglonafarnibmuscle atrophy

Substanzen

DexamethasonePiperidinesPyridineslonafarnibDibenzocycloheptenes

Autor:innen und Institutionen

  • Department of Nanobiomedical Science & BK21 NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, Korea.
  • Natural Product Research Institute, College of Pharmacy, Seoul National University, Seoul, Korea.
  • Department of Microbiology, College of Science & Technology, Dankook University, Cheonan, Korea.
  • Smart Animal Bio Institute, Dankook University, Cheonan, Korea.
  • Center for Bio-Medical Core Facility, Dankook University, Cheonan, Korea.
  • College of Science & Technology, Dankook University, Cheonan, Korea.

ORCID-Profile: Jung Keun Hyun

Förderung

  • National Research Foundation (NRF)
  • Ministry of Science and ICT (MSIT)
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Bae, S., Mai, V. H., Mun, S., Dong, D., Han, K., Park, S., & Hyun, J. K. (2025). Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13665

Vancouver

Bae S, Mai VH, Mun S, Dong D, Han K, Park S, et al. Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13665

BibTeX
@article{Bae2025,
  author = {Bae, Sanghoon and Mai, Van-Hieu and Mun, Seyoung and Dong, Dalong and Han, Kyudong and Park, Sunghyouk and Hyun, Jung Keun},
  title = {Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13665}
}
Kostenlos starten →